Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 31, Issue 6, Pages 495-498Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2022.2042252
Keywords
Breast cancer; triple negative breast cancer; combinations; antibody drug conjugate; sacituzumab govitecan; ladiratuzumab vedotin